Pharmaceutical company sponsored disease management programs: an alternative for tax-exempt MCOs and hospitals.
On April 25, 2002, the Internal Revenue Service finalized the proposed Corporate Sponsorship regulations. The changes made in the final regulations pertain to the proposed $79 ceiling on disregarded benefits, the 2 percent threshold for disregarded benefits, the scope of disregarded benefits, Web site hyperlinks, the inclusion of certain electronic publications in the definition of periodicals, the valuation date for substantial return benefits, and the scope of use or acknowledgement. The proposed regulations were discussed in the Winter 2002 issue of Managed Care Quarterly in an article titled the same as this one. This article is based on the final IRS regulations and therefore supersedes the original article published in the Winter 2002 issue.
Jedrey
Christopher M
CM
McDermott, Will & Emery, Boston, MA, USA.
Chaurette
Katherine A
KA
Winn
Lara Beth
LB
D019468:Disease Management; D004345:Drug Industry / Q000191:economics*; D005381:Financing, Organized / Q000331:legislation & jurisprudence*; D005607:Fraud / Q000331:legislation & jurisprudence; D006788:Hospitals, Voluntary / Q000191:economics* / Q000331:legislation & jurisprudence; D006801:Humans; D008329:Managed Care Programs / Q000191:economics* / Q000331:legislation & jurisprudence; D040541:Marketing / Q000331:legislation & jurisprudence; D009939:Organizations, Nonprofit / Q000191:economics / Q000331:legislation & jurisprudence; D016730:Program Development / Q000191:economics*; D019464:Tax Exemption / Q000331:legislation & jurisprudence*; D014481:United States; D037041:United States Government Agencies